AstraZeneca plc engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. The company was founded in 1992 and is based in London, the United Kingdom.
AZN Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Astrazeneca Plc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Astrazeneca Plc ranked in the 20th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for AZN, they are:
The company's compound free cash flow growth rate over the past 5.55 years comes in at -0.12%; that's greater than merely 15.14% of US stocks we're applying DCF forecasting to.
Relative to other stocks in its sector (Healthcare), Astrazeneca Plc has a reliance on debt greater than 63.79% of them.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Astrazeneca Plc? See PRGO, CPIX, PBYI, NRC, and RMD.
Technavio has been monitoring the post-traumatic stress disorder therapeutics market and it is poised to grow by USD 909.86 million during 2020-2024, progressing at a CAGR of over 9% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200525005262/en/ Technavio has announced its latest market research report titled Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market 2020-2024 (Graphic: Business Wire) Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Free Sample Repor...